catalyx space | $5,400,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
Marea Therapeutics
United States
- San Francisco, CA
- 20/06/2024
- Series A
- $190,000,000
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development and has the potential to become a new treatment for patients who remain at high risk of severe cardiovascular disease due to elevated remnant cholesterol and metabolic dysfunction. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology.
- Industry Biotechnology Research
- Website https://www.mareatx.com/
- LinkedIn https://www.linkedin.com/company/marea-therapeutics/
Related People
Josh LehrerFounder
United States -
Palo Alto, California
- Proven strategic leader in both large biopharma environment and in fast-paced biotech startup environments
- Track record building and leading a highly functioning development organization developing multiple programs (large and small molecules)
- Program and clinical/regulatory leadership from pre-IND through NDA approval and successful commercial launch, including negotiation of novel registrational endpoints, accelerated approval, breakthrough designation and rare disease experience.
- Leadership role in board and investor interactions, including supporting successful initial public offering, multiple highly successful financings and podium presentations at multiple finance conferences.
- As member of Senior Management Team, experience in building a biotech company from pre-IND/series A through 4+ billion market cap and NDA.
- Business development experience leading cross-functional team to evaluate in-licensing opportunities, led successful in-licensing of Phase 3 asset
- Basic science and translational experience in cardiovascular biology, active clinical practice in cardiology
Specialties: Board certified in internal medicine, cardiovascular medicine and nuclear cardiology.
Helex | $3,500,000 | (Nov 4, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)